Legend Biotech (LEGN) EBT (2019 - 2026)
Legend Biotech's (LEGN) quarterly EBT came in at -$53.8 million in Q1 2026, up 45.77% YoY from -$36.9 million in Q1 2025, and down 173.1% on a QoQ basis from -$19.7 million in Q4 2025.
Legend Biotech (LEGN) EBT (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of EBT data on file, last reported at -$53.8 million in Q1 2026.
- Quarterly EBT rose 45.77% year-over-year to -$53.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$237.4 million (down 20.21% YoY) and the FY2025 annual result came in at -$282.6 million, down 78.71% from the prior year.
- EBT slipped to -$53.8 million in Q1 2026, from -$19.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of $40.6 million in Q4 2024 to a low of -$198.8 million in Q2 2023.
- A 5-year average of -$85.9 million and a median of -$84.8 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT slumped 33858.75% — and 2024, when it surged 127.65%.
- Tracing LEGN's EBT over 5 years: stood at -$135.7 million in 2022, then dropped by 8.17% to -$146.8 million in 2023, then surged by 127.65% to $40.6 million in 2024, then plunged by 148.52% to -$19.7 million in 2025, then tumbled by 173.1% to -$53.8 million in 2026.
- The last three EBT figures came in at -$53.8 million (Q1 2026), -$19.7 million (Q4 2025), and -$39.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 541.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 312.46 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2,828.29 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 177.81 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn | 55.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 55.50 Mn |
| Mar 31, 2026 | -53.80 Mn |
| Dec 31, 2025 | -19.70 Mn |
| Sep 30, 2025 | -39.07 Mn |
| Jun 30, 2025 | -124.80 Mn |
| Mar 31, 2025 | -99.20 Mn |
| Dec 31, 2024 | 40.60 Mn |
| Sep 30, 2024 | -120.89 Mn |
| Jun 30, 2024 | -17.97 Mn |
| Mar 31, 2024 | -59.79 Mn |
| Dec 31, 2023 | -146.81 Mn |
| Sep 30, 2023 | -62.50 Mn |
| Jun 30, 2023 | -198.84 Mn |
| Mar 31, 2023 | -111.97 Mn |
| Dec 31, 2022 | -135.72 Mn |
| Sep 30, 2022 | -84.80 Mn |
| Jun 30, 2022 | -193.07 Mn |
| Mar 31, 2022 | -32.13 Mn |
| Dec 31, 2021 | -88.33 Mn |
| Sep 30, 2021 | -124.75 Mn |